Design and development of a delayed-release dose-flexible matrix tablet of tolfenamic acid for potential application in cancer therapy.
Tolfenamic acid (TFA), a Biopharmaceutics Classification System (BCS) class II drug, exhibits dissolution-limited absorption and significant gastric irritation when administered as conventional immediate-release formulations, limiting its potential for high-dose and long-term applications, including emerging anticancer...